Niaid DIR operational task order
Ended Awarded Last action
- Contract number
- 75N91024F00013
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $10,395,802
Award facts
- Contract value 90% obligated
- $11,491,778.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $2,645,802 | |
| Original award | $7,750,000 |
About this award
This is a $11,491,778.00 cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for NIAID DIR (Division of Intramural Research) operational support tasks with a period of performance through August 30, 2025. There is no set-aside designation on this award. Leidos Biomedical Research Inc. is a Federally Funded Research and Development Center (FFRDC) contractor for the National Cancer Institute (NCI) that provides comprehensive biomedical research and facilities support services to federal agencies, with a focus on the National Institutes of Health (NIH). The contract supports critical scientific research across multiple disease areas, including cancer, HIV/AIDS, influenza, COVID-19, and gene therapy.
Quick answers
Who was awarded contract 75N91024F00013?
75N91024F00013 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on August 31, 2024.
How much is contract 75N91024F00013 worth?
The government has obligated $10,395,802 on 75N91024F00013. Its current value, with exercised options, is $11,491,778.
Which agency awarded contract 75N91024F00013?
National Cancer Institute (National Institutes of Health) awarded 75N91024F00013, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract 75N91024F00013 an order under another contract?
Yes. 75N91024F00013 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91024F00013 competed?
The extent of competition for 75N91024F00013 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award